IONS
NASDAQIonis Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$54.37+0.25 (+0.46%)
01:30 PM07:45 PM
News · 26 weeks132+138%
2026-01-182026-07-12
Mix6190d
- Insider30(49%)
- Other15(25%)
- SEC Filings11(18%)
- Analyst3(5%)
- Earnings1(2%)
- Leadership1(2%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Reikes Peter N4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERSEC Form 4 filed by Director Hantson Ludwig4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERDirector Herman Joan E converted options into 5,220 shares, increasing direct ownership by 11% to 51,306 units (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERDirector Berthelsen Spencer R converted options into 5,220 shares, increasing direct ownership by 3% to 161,233 units (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- ANALYSTIonis Pharma downgraded by Wolfe ResearchWolfe Research downgraded Ionis Pharma from Outperform to Peer Perform
- PRIonis to hold second quarter 2026 financial results webcastWebcast scheduled for Wednesday, July 29 at 8:30 a.m. Eastern TimeIonis Pharmaceuticals, Inc. (NASDAQ:IONS) announced today that it will host a live webcast on Wednesday, July 29 at 8:30 a.m. Eastern Time to discuss its second quarter 2026 financial results and highlight progress on key programs.The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.About Ionis Pharmaceuticals, Inc.For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and
- PRIonis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease- Clinical outcomes: Diranersen demonstrated efficacy across all studied doses at 18 months, with consistent results across multiple prespecified clinical endpoints; the 60 mg dose showed the strongest response with slowing of clinical decline on the cognitive endpoints—42% on ADAS-Cog13 and 50% on MMSE—alongside a 26% slowing on CDR-SB - - Biomarker response: Diranersen is the first tau-directed therapy to demonstrate robust reductions in both CSF total tau, with mean reductions of 50–65%, and brain tau pathology, as measured by PET, across all studied doses in a Phase 2 study - - Dose response: CDR-SB results favored diranersen versus placebo across all studied doses; higher doses wer
- PRIonis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndromeIonis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the first participant has been dosed in the Phase 1-2 ASCEND study of ION337, an investigational RNA-targeted medicine for people living with Dravet syndrome, a rare, severe and lifelong neurological disorder. Dravet syndrome typically begins in infancy and is associated with prolonged seizures, developmental delays, cognitive impairments and an increased risk of sudden death. "The first participant to receive ION337 in the ASCEND study marks an important step toward advancing a potential disease modifying therapy for people living with Dravet syndrome," said Holly Kordasiewicz, Ph.D., executive vice president, chief developme
- SECIonis Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- INSIDEREVP, Chief Scientific Officer Bennett C Frank sold $1,744,623 worth of shares (20,536 units at $84.95) as part of a pre-agreed trading plan and acquired 15,000 shares as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 75,018 units (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERDirector Diaz Allene M. sold $863,637 worth of shares (10,111 units at $85.42) as part of a pre-agreed trading plan and exercised 10,111 shares at a strike of $47.11 (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDEREVP, Chief Development Officer Kordasiewicz Holly B. sold $30,517 worth of shares (362 units at $84.30) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 22,096 units (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- SECIonis Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- PRUpdate on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy– Study missed primary endpoint of composite outcome of cardiovascular (CV) mortality and recurrent CV events; in a pre-specified subgroup analysis, a nominally significant result was observed with eplontersen monotherapy – – Favorable safety profile consistent with previous results – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and partner AstraZeneca today announced that the CARDIO-TTRansform Phase 3 trial for eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy endpoint of the composite outcome of cardiovascular (CV) mortality and recurrent CV clinical events up to Week 140 compared with placebo. In this contemporary pati
- INSIDERSEC Form 4 filed by Director Yang Michael J.4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERSEC Form 4 filed by Director Loscalzo Joseph4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERSEC Form 4 filed by Director Herman Joan E4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERDirector Klein Joseph Iii exercised 11,518 shares at a strike of $39.94 and sold $910,416 worth of shares (11,518 units at $79.04) as part of a pre-agreed trading plan (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERSEC Form 4 filed by Director Hayden Michael R4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERSEC Form 4 filed by Director Diaz Allene M.4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERSEC Form 4 filed by Director Berthelsen Spencer R4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- PRIonis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome- Topline data from REVEAL anticipated in 2H 2027 - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that it has completed enrollment in the pivotal cohort (Cohort 1) of the global Phase 3 REVEAL study evaluating obudanersen (ION582), an investigational RNA-targeted medicine for people living with Angelman syndrome (AS), a serious and rare neurodevelopmental disorder associated with significant impairments in communication, physical function and cognition. The pivotal cohort enrolled 136 participants aged 2 to < 18 years old with a confirmed clinical diagnosis of AS with genetic confirmation of either a UBE3A deletion or UBE3A mutation. The adult cohort (Cohort 2) comprised of pa
- INSIDEREVP, Chief Business Officer Baroldi Joseph exercised 5,635 shares at a strike of $49.19 and sold $451,699 worth of shares (5,635 units at $80.16) as part of a pre-agreed trading plan (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDEREVP CLO & General Counsel O'Neil Patrick R. sold $245,520 worth of shares (3,069 units at $80.00) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 61,470 units (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDEREVP, Chf Clinical Develop Ofcr Schneider Eugene exercised 26,000 shares at a strike of $60.89 and sold $2,107,196 worth of shares (26,000 units at $81.05) as part of a pre-agreed trading plan (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
IONS FAQ
6 questionsWhat does Ionis Pharmaceuticals Inc. do?
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases...Where does IONS stock trade?
Ionis Pharmaceuticals Inc. (IONS) is listed on NASDAQ.What sector and industry is IONS in?
Ionis Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about IONS?
Ionis Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Peer Perform on 2026-07-16.What companies are similar to IONS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare IONS side-by-side with any of them on Quantisnow.How can I track IONS on Quantisnow?
Quantisnow aggregates Ionis Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IONS to receive live email and push alerts on every new disclosure.